Alnylam Pharmaceuticals vs BioNTech

Alnylam Pharmaceuticals (ALNY), health care, and BioNTech (BNTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Alnylam Pharmaceuticals and BioNTech are valued at about the same: $21B and $21B. Alnylam Pharmaceuticals's operating margin in its latest fiscal year was 13.5% and BioNTech's -49.0%. Over the past year Alnylam Pharmaceuticals's share price has moved -65.4% and BioNTech's -16.8%.

Key facts

Alnylam Pharmaceuticals market value
$21B
BioNTech market value
$21B
Alnylam Pharmaceuticals P/E
7.9
Alnylam Pharmaceuticals revenue
$3.7BFY to 2025-12-31
BioNTech revenue
$3.2BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Alnylam Pharmaceuticals vs BioNTech: every measure side by side
Measure Alnylam Pharmaceuticals BioNTech
SectorHealth CareHealth Care
Country United States Germany
Fiscal year ends2025-12-312025-12-31
Size
Market cap$21Blower$21Bhigher
Revenue$3.7Bhigher$3.2Blower
Earnings$313.7Mhigher-$1.3Blower
Employees2,500lower7,807higher
Total assets$5Blower$24.4Bhigher
Valuation
P/E7.9—
P/S5.6lower6.6higher
P/B5.8—
Dividend yield0.00%—
Profitability
Operating margin13.5%higher-49.0%lower
Balance sheet
Net assets$789.2Mlower$21.3Bhigher
Total liabilities$4.2Bhigher$3.1Blower
Total debt——
Cash on hand$1.7Blower$8.5Bhigher
Price change
Today-2.02%lower-0.47%higher
1 year-65.4%lower-16.8%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Alnylam Pharmaceuticals only (3)

BioNTech only (3)

Percentages are each holding's share of that investor's reported portfolio (under "Both": Alnylam Pharmaceuticals / BioNTech). Who owns ALNY · Who owns BNTX

Further comparisons

Learn

Questions and answers

Which is bigger, Alnylam Pharmaceuticals or BioNTech?

By market value, BioNTech is the larger: $21B against $21B for Alnylam Pharmaceuticals. By revenue in its latest fiscal year, Alnylam Pharmaceuticals is the larger: $3.7B against $3.2B for BioNTech.

Which has the higher operating margin?

Alnylam Pharmaceuticals: 13.5%, against -49.0% for BioNTech. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Alnylam Pharmaceuticals and BioNTech?

In their latest 13F filings, Dodge & Cox team holds both.

Cite this page

Funkfolio, “Alnylam Pharmaceuticals vs BioNTech”, data as of 18 November 2026. https://funkfolio.com/compare/alny-vs-bntx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.